Harbour BioMed and BioMap Launch MegaStream TechBio AI-native Pipeline Company

Harbour BioMed, global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology, and other disease areas, and BioMap, a leader in AI foundation models for life sciences, have launched MegaStream TechBio, a collaborative initiative aimed at advancing the use of artificial intelligence in biologics research and development. The project brings together Harbour BioMed’s drug discovery and development capabilities with BioMap’s life sciences foundation models to support the design and development of complex biologic therapies.

The platform will focus on integrating AI models with experimental and clinical research workflows to improve target identification, antibody discovery and drug optimization. The effort is intended to accelerate development timelines while increasing the efficiency of biologics research programs.

MegaStream will integrate a proprietary ecosystem of exclusive datasets with purpose-built large models and a large-scale innovative pipeline portfolio into an AI-powered R&D engine. By replacing traditional repetitive screening with AI model predictions and targeted, high-precision validation, and leveraging the power of generative AI models, the platform will produce pipeline molecules with superior performance metrics, more comprehensive multi-objective optimization, and more precise programmable control.

Posted by MedCloudInsider Editors on 06/16/2026